Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis.
Crit Care Med
; 52(6): e314-e322, 2024 06 01.
Article
in En
| MEDLINE
| ID: mdl-38363176
ABSTRACT
OBJECTIVES:
Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening disease. Despite being considered the gold standard treatment scheme, inhaled nitric oxide (iNO) is not readily available in settings with limited resources. Therefore, in recent years, research on related drugs is being actively pursued. Herein, we aimed to use random-effects network meta-analysis to evaluate the efficacy and associated mortality of different PPHN therapies. DATA SOURCES We electronically searched the PubMed, Embase, and Cochrane Library for data up to January 27, 2023. STUDY SELECTION Randomized controlled trials involving neonates with PPHN assessing efficacy and mortality of various treatments. DATA EXTRACTION Details of study population, treatments, and outcomes were extracted. DATASYNTHESIS:
Direct pairwise comparisons and a network meta-analysis was performed under random effects. The ranking probability was further assessed based on the surface under the cumulative ranking curve (SUCRA). We analyzed 23 randomized clinical trials involving 902 newborns with PPHN. Sixteen different treatment strategies were compared with each other and conventional therapy (CON). A median concentration of 10-20 parts per million (ppm) iNO (MNO) coupled with sildenafil orally administered at a dose of 1-3 mg/kg/dose every 6-8 hours (OSID) demonstrated the best efficacy (MNO + OSID vs. CON odds ratio [OR] = 27.53, 95% CI, 2.36-321.75; SUCRA = 0.818, ranking first; moderate quality). OSID combined with milrinone administered IV also performed well in terms of efficacy (OSID + milrinone vs. CON OR = 25.13, 95% CI = 1.67-377.78; SUCRA = 0.811, ranking second; low quality) and mortality reduction (CON vs. OSID + milrinone OR = 25.13, 95% CI = 1.67-377.78; SUCRA = 0.786, ranking last; low quality).CONCLUSIONS:
MNO + OSID is the most effective PPHN treatment. If iNO is not available, OSID + milrinone is preferred.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Persistent Fetal Circulation Syndrome
/
Sildenafil Citrate
/
Network Meta-Analysis
/
Nitric Oxide
Type of study:
Clinical_trials
/
Systematic_reviews
Limits:
Humans
/
Newborn
Language:
En
Journal:
Crit Care Med
Year:
2024
Document type:
Article
Affiliation country:
China